RNS Number:2622Y
Lombard Medical Technologies PLC
10 February 2006

          Lombard Medical Announces that Abdominal Aortic Aneurysm Screening
                                 to Commence in the US

London, UK, 10 February 2006 - Lombard Medical Technologies PLC (AIM: LMT)
reports that the US Congress yesterday passed legislation for one-time
ultrasound screening to commence for abdominal aortic aneurysms (AAA) in the US.

With this legislation, the Social Security Act will be amended to provide
coverage of the Medicare program, which provides health care to the 41 million
elderly in the US who are most at risk from this type of AAA disease.  Patients
at risk for AAA will receive the ultrasound screening benefit as part of their
"Welcome to Medicare" physical, in the hope that more AAA's will be diagnosed
and treated with a stent graft.  The covered patient population includes men age
65 and over who have smoked more than 100 cigarettes in their lives, plus women
with a family history of AAA.  Coverage will begin in early 2007.

Alistair Taylor, Executive Chairman of Lombard said:

"The commencement of this screening programme in the US has the potential to
save thousands of lives.  The great majority of patients only discover the
presence of an aneurysm when it ruptures with potentially fatal effects.  These
lives can be saved through preventative screening, and, where necessary,
insertion of a stent graft to restore normal blood flow.

"There is an increasing body of evidence that suggests that Lombard Medical's
Aorfix(TM) stent graft is the only device which can serve the AAA market
effectively as it does not develop endoleaks, does not migrate and can
effectively treat severely angulated necks."

Enquiries:

Lombard Medical Technologies PLC
Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer

Financial Dynamics
Tel: 020 7831 3113
David Yates / John Gilbert


Notes to editors

Lombard Medical Technologies is a medical devices company developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, Aorfix(TM), is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death.

Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in
the US and the market is estimated to be worth approximately US$2 billion by
2010.  Aorfix(TM) is currently being commercialised in the EU, with US clinical
trials expected to commence during 2006.  The Company has a strategic
collaboration with one of the world's leading medical devices companies, Boston
Scientific.

Lombard Medical has recently successfully completed its initial public offering
on AIM and was admitted to listing in December 2005, raising #23.9 million, net
of expenses.  The Company, based in Oxfordshire & Yorkshire, currently employs
47 people.

Further background on the Company can be found at www.lombardmedical.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCXBLFFQLBEBBD
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.